Xue-Feng Kan, Bin Liang, Xiao-Lin Zhang, Lei Yu, Yao-Chang Luo, Shi Zhou et al. Transarterial chemoembolization plus apatinib for unresectable hepatocellular carcinoma: a multicenter, randomized, open-label, phase III trial. // BMC Medicine. – 2025. – DOI: 10.1186/s12916-025-04159-y. – URL: https://doi.org/10.1186/s12916-025-04159-y
Xue-Feng Kan, Bin Liang, Xiao-Lin Zhang, Lei Yu, Yao-Chang Luo, Shi Zhou, Rui-Bao Liu, Guo-Hui Xu, Hai-Liang Li, Zheng-Yin Liao, Hua Xiang, Wei Lu, Lin-Feng Xu, Yi-Long Ma, Xiang-Wen Xia, Kun Qian, Xiang-Jun Dong, Fu Xiong, Song-Lin Song, Chang Zhao, Ming Huang, & Chuan-Sheng Zheng (2025). Transarterial chemoembolization plus apatinib for unresectable hepatocellular carcinoma: a multicenter, randomized, open-label, phase III trial. BMC Medicine. https://doi.org/10.1186/s12916-025-04159-y
Xue-Feng Kan, et al. “Transarterial chemoembolization plus apatinib for unresectable hepatocellular carcinoma: a multicenter, randomized, open-label, phase III trial.” BMC Medicine, 2025. doi:10.1186/s12916-025-04159-y.
@article{Kan2025,
title = {Transarterial chemoembolization plus apatinib for unresectable hepatocellular carcinoma: a multicenter, randomized, open-label, phase III trial},
author = {Kan, Xue-Feng and Liang, Bin and Zhang, Xiao-Lin and Yu, Lei and Luo, Yao-Chang and Zhou, Shi and Liu, Rui-Bao and Xu, Guo-Hui and Li, Hai-Liang and Liao, Zheng-Yin and Xiang, Hua and Lu, Wei and Xu, Lin-Feng and Ma, Yi-Long and Xia, Xiang-Wen and Qian, Kun and Dong, Xiang-Jun and Xiong, Fu and Song, Song-Lin and Zhao, Chang and Huang, Ming and Zheng, Chuan-Sheng},
journal = {BMC Medicine},
year = {2025},
doi = {10.1186/s12916-025-04159-y},
url = {https://doi.org/10.1186/s12916-025-04159-y}
}